j9九游会官方网站

Founded in 2004, Shandong Keyuan Pharmaceutical Co., Ltd. is the core member of Linuo Healthcare Industry. It is a high-tech company dedicated to the R&D, manufacture and sales of APIs. Its portfolio covers anti-diabetic agents, cardiovascular agents and anesthetics. Keyuan has established strategic partnership with many renowned international companies.  
The company consistently upholds the entrepreneurship and practical working style. With the accumulative industrial strength and the technology-guided and people-oriented business principle, the company has gradually become the backbone of Shandong synthetic API industry.  
The company produces gliclazide, metformin hydrochloride, isosorbide mononitrate, isosorbide dinitrate, isoclurance, ropivacaine hydrochloride and clarithromycin lactobionate.
Main accreditations: gliclazide, isosorbide monoitrate mixed powder and other products have obtained the accreditation of CEP. PLNS has obtained the accreditation of FDA.
In March 2016, Keyuan was listed on NEEQ. NEEQ varies the choice of investment and expands the withdrawal of venture investment institutions. Being listed on NEEQ provides more financing channels for the company, expanding the financing platform, and make the financing more flexible, which lays an increasingly solid foundation for the further development of the company and strengthens its international competitiveness. Keyuan will make itself a larger and stronger company with the help of the capital market.
Keyuan upholds the motto of Serving the country with industry and striving for excellence and is devoted to establishing the largest production base of anti-diabetic agents, cardiovascular agents and anesthetics for the benefit of the patients.